Metoclopramide

Metoclopramide dosing may be weight based; ensure accuracy of documented weight before administration		
Form & Storage	10mg per 2mL ampoule	Store in original box away from light.
Reconstitution	Already in solution	
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5%	
Administration	If inadvertent exposure to light occurs, ampoules showing a yellow discolouration must be discarded. **IV Injection** Give slowly over at least 3 minutes. **IM injection** No dilution required. **Continuous SC Infusion** Dilute with sodium chloride 0.9%	
Adverse Drug Reactions	• Extrapyramidal disorders may occur, particularly in children and young adults, and/or when high doses are used. Metoclopramide should be discontinued immediately in the event of extrapyramidal symptoms. • Increased risk of dystonic reactions (including oculogyric crises) in elderly and in young patients, particularly girls and young women, use of metoclopramide should be restricted to those situations for which there is no safer alternative. Lower doses should be used in these patient groups (maximum 500 micrograms/kg for high-dose therapy).	
Additional Information	• In order to avoid overdose, a minimal interval of 6 hours between two administrations is to be respected, even in case of vomiting or rejection of the dose. • Administration via syringe driver is unlicensed and may increase the administration risk rating. To mitigate these risks: ○ Contact the Pharmacy Department or Palliative care team for further guidance. ○ Consult the Palliative Care Formulary accessible on www.medicinescomplete.com or the Syringe Driver Survey Database (SDSD) (available after registration on www.palliativedrugs.com) for guidance on syringe driver compatibility.	

Information provided relates to Metoclopramide manufactured by Mercury Pharmaceuticals.